Latest Articles
-
Ten-Year Tally: Pfizer Stock Delivers $68 Bil Gain
In the last decade, Pfizer (PFE) stock has returned a notable $68 Bil back to its shareholders through cold, hard cash via dividends and buybacks. Let’s look at some numbers and compare how this payout power stacks up against the marketR...
-
What Could Send Pfizer Stock Soaring
Pfizer has demonstrated remarkable rallies, with its stock surging over 30% in under two months during key periods like 8232021 and 12152021. These swift upswings have rewarded investors with substantial gains. If similar catalysts emerge, Pfizer...
-
Buy or Sell Pfizer Stock?
We believe there are a few things to fear in PFE stock given its overall Weak operating performance and financial condition. This is aligned with the stock’s Low valuation because of which we think it is Fairly Priced . Below is our asses...
-
What Can Cause Pfizer Stock To Crash?
Pfizer (PFE) is facing threats. Even the biggest names aren’t invincible. Stocks can drop sharply without warning – wiping out months or years of gains in a matter of weeks. History shows that sudden market swings can hit any company,...
-
What Could Send Pfizer Stock Soaring
Pfizer has demonstrated remarkable rallies, with its stock surging over 30% in under two months during key periods like 8232021 and 12152021. These swift upswings have rewarded investors with substantial gains. If similar catalysts emerge, Pfizer...
-
A Decade of Rewards: $68 Bil From Pfizer Stock
In the last decade, Pfizer (PFE) stock has returned a notable $68 Bil back to its shareholders through cold, hard cash via dividends and buybacks. Let’s look at some numbers and compare how this payout power stacks up against the marketR...
-
Pfizer Stock Capital Return Hits $68 Bil
In the last decade, Pfizer (PFE) stock has returned a notable $68 Bil back to its shareholders through cold, hard cash via dividends and buybacks. Let’s look at some numbers and compare how this payout power stacks up against the marketR...
-
Pfizer Stock Shares $68 Bil Success With Investors
In the last decade, Pfizer (PFE) stock has returned a notable $68 Bil back to its shareholders through cold, hard cash via dividends and buybacks. Let’s look at some numbers and compare how this payout power stacks up against the marketR...
-
Pfizer Stock To $32?
Our multi-factor assessment suggests that it may be time to buy more shares of PFE stock. We have, overall, a positive view of the stock, and a price of $32 may not be out of reach. We believe there is a near-equal mix of good and bad in PFE sto...
-
What Could Send Pfizer Stock Soaring
Pfizer has demonstrated remarkable rallies, with its stock surging over 30% in under two months during in 2021. These swift upswings have rewarded investors with substantial gains. If similar catalysts emerge, Pfizer shares could be poised for an...
-
Pfizer Stock Pays Out $50 Bil to Investors in 10 Years
In the last decade, Pfizer (PFE) stock has returned $50 Bil back to its shareholders through cold, hard cash via dividends and buybacks. Let’s look at some numbers and compare how this payout power stacks up against the market’s bigge...
-
PFE Surges 6.8% In A Single Day, Time To Buy The Stock?
We believe there is a near-equal mix of good and bad in PFE stock given its overall Moderate operating performance and financial condition. Considering stock’s Low valuation we think it is Attractive . Here is our multi-factor assessment. ...
-
Is Pfizer Stock A Buy At $25?
Pfizer stock (NYSE: PFE) presents an attractive investment opportunity at its current price of approximately $25, driven by compelling valuations and recent policy developments that could provide additional upside catalysts. Pfizer trades at a s...
-
S&P 500 Movers | Winners: PFE, MRK, DHR | Losers: ALB, MGM, COF
On Tuesday, September 30, a market-wide surge lifted the S&P 500 rising 0.41%, the Dow 30 rising 0.18%, and the Nasdaq 100 rising 0.28%. Gains were broad-based, though not every stock joined the rally. List of S&P 500 Winners ...
-
PFE Has Paid Out $50 Bil to Investors in the Past Decade
In the last decade, Pfizer (PFE) has returned $50 Bil back to its shareholders through cold, hard cash via dividends and buybacks. Let’s look at some numbers and compare how this payout power stacks up against the market’s biggest cap...
